Prostate cancer: endogenous chemical castration.

We report treatment of intermediate risk prostate cancer in a patient with a brief period of androgen deprivation secondary to a pituitary adenoma. This was a patient with intermediate risk prostate cancer diagnosed in the setting of an elevated prostate-specific antigen (PSA).

The patient subsequently demonstrated a decline in PSA along with symptoms of hypogonadism and visual disturbance, and was consequently found to have a pituitary tumour. Trans-sphenoidal resection of the sellar mass was performed with normalisation of hormone profiles. The patient subsequently completed a course of radiation therapy for prostate cancer with PSA nadir to undetectable levels without evidence of biochemical recurrence at 7 months follow-up.

BMJ case reports. 2016 Apr 28*** epublish ***

Olugbemisola Oredein McCoy, Michaella M Prasad, Natalie Singer

Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA., Department of Urology, Medical University of South Carolina, Charleston, South Carolina, USA., Department of Urology, Cincinnati VA Medical Center, Cincinnati, Ohio, USA.